用于2型糖尿病治疗的钠-葡萄糖协同转运蛋白2抑制剂
SGLT2 Inhibitors for Type 2 Diabetes Mellitus Treatment.
作者信息
Plodkowski Raymond A, McGarvey Megan E, Huribal Heather M, Reisinger-Kindle Keith, Kramer Bradley, Solomon Mordecai, Nguyen Quang T
机构信息
is a former chief of endocrinology and was an endocrinologist at the VA Sierra Nevada Health Care System in Reno. Dr. Plodkowski, , and are endocrinologists in the Division of Endocrinology, and Dr. McGarvey is also the associate program director of the Endocrinology Fellowship, all at Scripps Clinic in San Diego. Dr. Nguyen is the medical director of Las Vegas Endocrinology and an adjunct associate professor of medicine at Touro University Nevada College of Osteopathic Medicine, both in Nevada, and a clinical associate professor of clinical education at Arizona College of Osteopathic Medicine in Glendale, California. and are medical students at Touro University Nevada College of Osteopathic Medicine. is a senior medical resident at Valley Hospital Medical Center/Touro University.
出版信息
Fed Pract. 2015 Oct;32(Suppl 11):8S-15S.
Abstract
SGLT2 inhibitors are plausible second-line drugs that provide powerful additional A-lowering effects while inducing weight loss without hypoglycemia.
摘要
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂是一种合理的二线药物，在不引起低血糖的情况下，能显著增强降血糖效果并减轻体重。
相似文献
1
SGLT2 Inhibitors for Type 2 Diabetes Mellitus Treatment.用于2型糖尿病治疗的钠-葡萄糖协同转运蛋白2抑制剂
Fed Pract. 2015 Oct;32(Suppl 11):8S-15S.
2
Second-line Glucose-Lowering Therapy in Type 2 Diabetes Mellitus.2 型糖尿病的二线降糖治疗。
Curr Diab Rep. 2019 Jul 8;19(8):54. doi: 10.1007/s11892-019-1171-0.
3
Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂：聚焦于肾脏治疗2型糖尿病。
Ther Adv Endocrinol Metab. 2014 Oct;5(5):124-36. doi: 10.1177/2042018814553965.
4
SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.SGLT2 抑制剂控制 2 型糖尿病患者的血糖：一个老问题的新方法。
Postgrad Med. 2014 Jan;126(1):111-7. doi: 10.3810/pgm.2014.01.2731.
5
Effects of Sodium-glucose Cotransporter 2 Inhibitor Monotherapy on Weight Changes in Patients With Type 2 Diabetes Mellitus: a Bayesian Network Meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂单药治疗对 2 型糖尿病患者体重变化的影响：一项贝叶斯网状 Meta 分析。
Clin Ther. 2019 Feb;41(2):322-334.e11. doi: 10.1016/j.clinthera.2019.01.001. Epub 2019 Jan 30.
6
Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus.低SGLT2/SGLT1选择性的钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病患者循环胰高血糖素样肽1水平的影响
J Clin Med Res. 2017 Sep;9(9):745-753. doi: 10.14740/jocmr3112w. Epub 2017 Jul 27.
7
Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.钠-葡萄糖共转运蛋白 2 抑制剂与磺脲类药物在二甲双胍控制不佳的 2 型糖尿病患者中的比较：一项随机对照试验的荟萃分析。
Clin Drug Investig. 2019 Jun;39(6):521-531. doi: 10.1007/s40261-019-00781-w.
8
Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.卡格列净对2型糖尿病患者钠-葡萄糖协同转运蛋白2（SGLT2）的抑制作用
Cardiovasc Hematol Agents Med Chem. 2013 Sep;11(3):203-6. doi: 10.2174/187152571103140120103032.
9
Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.联合 SGLT1 和 SGLT2 抑制剂及其在糖尿病治疗中的作用。
Diabetes Technol Ther. 2018 Jun;20(S2):S269-S277. doi: 10.1089/dia.2018.0081.
10
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study.在真实临床实践中使用 SGLT2 抑制剂与肾脏结局的关联（CVD-REAL 3）：一项多国家观察性队列研究。
Lancet Diabetes Endocrinol. 2020 Jan;8(1):27-35. doi: 10.1016/S2213-8587(19)30384-5.
引用本文的文献
1
The real-world anti-inflammatory effect of SGLT2i in patients with chronic heart failure.钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）在慢性心力衰竭患者中的真实世界抗炎作用。
J Med Life. 2025 Feb;18(2):155-164. doi: 10.25122/jml-2025-0011.
2
Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours.库欣综合征、肢端肥大症和神经内分泌肿瘤继发糖尿病的实用治疗方法。
Front Endocrinol (Lausanne). 2023 Sep 28;14:1248985. doi: 10.3389/fendo.2023.1248985. eCollection 2023.
3
Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India.达格列净与恩格列净在印度2型糖尿病患者中的安全性和疗效比较。
Rev Assoc Med Bras (1992). 2023 Aug 14;69(8):e20230090. doi: 10.1590/1806-9282.20230090. eCollection 2023.
4
Potential Therapeutic Targets for the Management of Diabetes Mellitus Type 2.2 型糖尿病管理的潜在治疗靶点。
Curr Med Chem. 2024;31(21):3167-3181. doi: 10.2174/0929867330666230501172557.
5
A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂诱发正常血糖性糖尿病酮症酸中毒治疗前景的文献综述
Cureus. 2022 Sep 27;14(9):e29652. doi: 10.7759/cureus.29652. eCollection 2022 Sep.
6
Comparison of Cardiovascular Outcomes Between Dapagliflozin and Empagliflozin in Patients With Type 2 Diabetes: A Meta-Analysis.达格列净与恩格列净治疗2型糖尿病患者心血管结局的比较：一项荟萃分析
Cureus. 2022 Jul 26;14(7):e27277. doi: 10.7759/cureus.27277. eCollection 2022 Jul.
7
Oral GLP1 Analog: Where Does the Tide Go?口服胰高血糖素样肽-1类似物：何去何从？
Clin Med Insights Endocrinol Diabetes. 2020 Dec 28;13:1179551420984130. doi: 10.1177/1179551420984130. eCollection 2020.
本文引用的文献
1
Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects.恩格列净（BI 10773），一种强效且选择性的 SGLT2 抑制剂，可在健康受试者中引起剂量依赖性的糖尿。
Clin Pharmacol Drug Dev. 2013 Apr;2(2):152-61. doi: 10.1002/cpdd.16. Epub 2013 Mar 27.
2
AACE/ACE comprehensive diabetes management algorithm 2015.美国临床内分泌医师协会/美国内分泌学会2015年糖尿病综合管理算法
Endocr Pract. 2015 Apr;21(4):438-47. doi: 10.4158/EP15693.CS. Epub 2015 Apr 15.
3
Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.恩格列净单药治疗对日本2型糖尿病患者餐后血糖及24小时血糖变异性的影响：一项随机、双盲、安慰剂对照的4周研究。
Cardiovasc Diabetol. 2015 Jan 30;14:11. doi: 10.1186/s12933-014-0169-9.
4
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.钠-葡萄糖协同转运蛋白2抑制剂与心血管风险：提出的作用途径及正在进行的结局试验综述
Diab Vasc Dis Res. 2015 Mar;12(2):90-100. doi: 10.1177/1479164114559852. Epub 2015 Jan 14.
5
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetes.钠-葡萄糖共转运蛋白 2 抑制剂坎格列净联合胰岛素治疗 2 型糖尿病患者的疗效和安全性。
Diabetes Care. 2015 Mar;38(3):403-11. doi: 10.2337/dc14-1237. Epub 2014 Dec 2.
6
Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.卡格列净与达格列净的药效学差异：一项随机、双盲、交叉研究的结果
Diabetes Obes Metab. 2015 Feb;17(2):188-97. doi: 10.1111/dom.12418. Epub 2015 Jan 5.
7
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin.二甲双胍单药治疗血糖控制不佳的 2 型糖尿病的双联附加治疗：一项比较沙格列汀加达格列净双联附加治疗与沙格列汀或达格列净单药附加治疗加至二甲双胍的随机、双盲试验。
Diabetes Care. 2015 Mar;38(3):376-83. doi: 10.2337/dc14-1142. Epub 2014 Oct 28.
8
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.恩格列净可降低 2 型糖尿病合并高血压患者的血压。
Diabetes Care. 2015 Mar;38(3):420-8. doi: 10.2337/dc14-1096. Epub 2014 Sep 30.
9
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.卡格列净在二甲双胍治疗的 2 型糖尿病患者中提供了超过 104 周的持久血糖改善和体重减轻，优于格列美脲：一项随机、双盲、3 期研究。
Diabetes Care. 2015 Mar;38(3):355-64. doi: 10.2337/dc13-2762. Epub 2014 Sep 9.
10
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.卡格列净在2型糖尿病合并3期肾病患者中的疗效和安全性。
Am J Nephrol. 2014;40(1):64-74. doi: 10.1159/000364909. Epub 2014 Jul 17.
Zotero 插件